KoreaTimes(779) - Bio, Business, page 1

Entertainment
& Arts

Sports

World

SCMP
Asia

Video

Photos

Site Map E-paper Subscribe Register LogIn
Site Map E-paper Subscribe Register LogIn

Business

Bio

Sun, July 3, 2022 | 17:49

Korea's bio industry at turning point after pandemic

SK Bioscience, Samsung Biologics and other Korean biotech companies are soaring to new heights as they succeed in locally developing vaccines, winning orders to manufacture the drugs and developing treatments for COVID-19, according industry officials, Thursday. “It is obvious that the pandemic raised the importance of securing proprietary vaccine development and manufacturin...

Baek Byung-yeul | 2022-07-03 10:25

SK Bioscience gets final approval for Korea's 1st COVID-19 vaccine

SK Bioscience's SKYCovione, also known as GBP510, was approved for use, Wednesday, becoming Korea's first locally-developed COVID-19 vaccine to get the green light. The Ministry of Food and Drug Safety (MFDS) announced that it authorized the use of the recombinant protein-based vaccine.

Park Jae-hyuk | 2022-06-29 16:44

Korea approves use of 1st local COVID-19 vaccine from SK Bioscience

The government approved the use of SKYCovione, Wednesday, the country's first locally developed COVID-19 vaccine by SK Bioscience, taking a major step toward achieving vaccine sovereignty in the fight against the pandemic.

2022-06-29 15:02

SK Bioscience COVID-19 vaccine closer to final approval

SK Bioscience has moved one step closer toward rolling out Korea's first COVID-19 vaccine, as the government advisory panel of pharmaceutical experts determined that a license for the use of the vaccine can be granted, according to the Ministry of Food and Drug Safety (MFDS), Monday. “The COVID-19 vaccine developed by SK Bioscience is the first COVID-19 vaccine produced in Ko...

Baek Byung-yeul | 2022-06-27 15:32

[INTERVIEW] Embracing routine PCR test is key to preventing next virus: Seegene CEO

It's the middle of June and there is a chance that the country's new COVID-19 cases will surge again because of a rise in Omicron sub-variants currently being detected in the U.S. and Europe. The U.S. recently lifted its mandatory COVID testing for overseas travelers arriving by plane, which means that visitors no longer need to show negative test results or proof of recovery...

Kim Yoo-chul | 2022-06-16 12:34

SK Bioscience to test own COVID vaccine as booster

SK Bioscience is set to conduct Phase 3 clinical trials of its COVID-19 vaccine in overseas countries to check its effectiveness as a booster shot. The biotech company also expects its vaccine could be approved by a health agency here, according to a company official, Monday.

Baek Byung-yeul | 2022-06-06 16:38

[INTERVIEW] Korea should strengthen ecosystem for clinical trials

Over the last few years, the government has been supporting its strategy to help the country rise as a biotechnology hub in Asia given Korea's long-time competiveness in product manufacturing. The country's advantages in terms of having excellent infrastructure, workforce and IT platform have truly been beneficial amid COVID-19 as a number of biotechnology companies, includin...

Kim Yoo-chul | 2022-06-02 15:24

Samsung Biologics establishes one-stop mRNA vaccine production capability at Songdo plant

Samsung Biologics, the biotech arm of Korea's Samsung Group, has established a one-stop production capability for manufacturing messenger RNA (mRNA) vaccines by newly adding an mRNA vaccine substance production facility at the plant, a company official said Thursday.

2022-06-02 11:21

[INTERVIEW] Immunomic Therapeutics CEO expects meaningful test results for brain tumor drug

William Hearl, CEO of Immunomic Therapeutics, the U.S. subsidiary of the Korean biotech company, HLB, said that the company expects meaningful test results from its Phase 2 clinical trials of a drug for glioblastoma by August of this year at the latest.

Baek Byung-yeul | 2022-05-26 16:03

HLB gets positive Phase 3 data with liver cancer treatment

HLB has taken a step closer to the global commercialization of its anticancer treatment Rivoceranib as it secured statistical significance in Phase 3 global clinical trials of the drug, according to the local biotech company, Sunday.

Baek Byung-yeul | 2022-05-15 16:23

1 2 3 4

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.